Viral Vector Vaccines Market Size and Share Analysis

1

• Viral Vector Vaccines Market to Surge at a Robust
  Pace In Terms Of Revenue Over 2033
• The global viral vector vaccines market was
  valued at US 738.4 million in 2022 and is
  projected to expand at a CAGR of 3.9 over the
  forecast period (2023 to 2033), as per this
  latest market study by Persistence Market
  Research. Demand for viral vector vaccines is set
  to reach US 1.23 billion by the end of 2033.
• Development of gene therapy has paved the way for
  the use of viral vectors in vaccine development.
  This has led to the expansion of viral vector
  technology beyond traditional vaccine
  development.
• Advancements in technology have allowed for the
  creation of more efficient and safer viral vector
  vaccines. Use of synthetic biology and
  CRISPR/Cas9 has allowed for more targeted and
  precise gene editing. Use of viral vectors in
  gene therapy has led to the expansion of viral
  vector technology beyond traditional vaccine
  development.
• The success of gene therapies for genetic
  disorders has demonstrated the potential of viral
  vectors to target specific cells or tissues.
  Viral vector vaccines, which use weakened or
  modified viruses to deliver genetic material
  into cells to stimulate an immune response, have
  shown promise in treating a range of diseases,
  including cancer, HIV/AIDS, and other infectious
  diseases.
• Other than this, an increase in government and
  private funding for the development of viral
  vector vaccines has encouraged pharmaceutical
  and biotech companies to invest in the
  development of these vaccines. Furthermore, the
  increase in government and private funding for
  research and development of gene therapy and
  viral vector vaccines has encouraged
  pharmaceutical and biotech companies to invest
  in the development of these therapies. All these
  factors will boost the global demand for this
  market over the forecast period.
• In a nutshell, the Persistence Market Research
  report is a must-read for start-ups, industry
  players, investors, researchers, consultants,
  business strategists, and all those who are
  looking to understand this industry. Get a
  glance at the report at https//www.persistencem
  arketresearch.com/market- research/viral-vector-v
  accines-market.asp
• Key Takeaways from Market Study
• The global viral vector vaccines market is
  predicted to reach a valuation of US 1.23
  billion by the end of 2033.
• The adults segment held a market share of 64.5
  in 2022.
• By distribution channel, hospitals led with a
  market share of 67.5 in 2022.
• The Middle East and Africa dominated the global
  market with North Africa contributing US
• 205.6 million in revenue in 2022.
• North America accounted for 28.7 market share in
  2022.
• Advancements in biotechnology genetic
  engineering and increased RD activities are
  expected to boost the demand for viral vector
  vaccines over the forecast period, says an
  analyst at Persistence Market Research.
• Market Competition

2

• Leading manufacturers of viral vector vaccines
  are focusing on developing partnerships and
  collaborations with other companies as well as
  government institutes to expand their RD
  activities related to various vaccines. Apart
  from this, they also involve themselves in
  expanding manufacturing capacity and
  diversifying product portfolios.
• In January 2021, Merck and UNICEF inked a
  contract to create the Ebola vaccine stockpile
  with ERVEBO. The ERVEBO vaccination is a
  significant milestone in the battle against
  Ebola, resulting from groundbreaking innovation
  and worldwide collaboration. The vaccination is
  recommended for individuals aged 18 and up to
  prevent illness caused by the Zaire ebolavirus.
• What Does the Report Cover?
• Persistence Market Research offers a unique
  perspective and actionable insights on the viral
  vector vaccines market in its latest study,
  presenting a historical demand assessment for
  2017 to 2022 and projections for 2023 to 2033.
• The research study is based on patient (pediatric
  and adults) and distribution channel (hospitals
  and government institutes), across four regions
  of the world (North America, Europe, East Asia,
  and the Middle East and Africa MEA).
• For additional insights on how the growth of the
  viral vector vaccines market will unfold over the
  decade, write to the analyst at
  media_at_persistencemarketresearch.com
• Persistence Market Researchs Expertise in Life
  Sciences and Transformational Health
• Our expert team of industry analysts comprising
  management graduates, medical professionals,
  engineers, and project managers provides insights
  on emerging therapy areas, diagnostic tools,
  medical devices and components, reimbursement
  and market access, biotechnology, and life
  science research products and services to equip
  decision-makers with sound inputs and strategic
  recommendations.
• About Persistence Market Research
• Business intelligence is the foundation of every
  business model employed by Persistence Market
  Research. Multi-dimensional sources are being put
  to work, which include big data, customer
  experience analytics, and real-time data
  collection. Thus, working on micros by
  Persistence Market Research helps companies
  overcome their macro business challenges.
• Persistence Market Research is always way ahead
  of its time. In other words, it tables market
  solutions by stepping into the
  companies/clients shoes much before they
  themselves have a sneak pick into the market.
  The pro-active approach followed by experts at
  Persistence Market Research helps
  companies/clients lay their hands on
  techno-commercial insights beforehand, so that
  the subsequent course of action could be
  simplified on their part.
• Contact
• Persistence Market Research Teerth Technospace,
  Unit B-704

3
Survey Number 103, Baner Mumbai Bangalore
Highway Pune 411045 India Email
sales_at_persistencemarketresearch.com Web
https//www.persistencemarketresearch.com